Orthofix国际 OFIX 深 沪
已收盘 10-17 16:00:00 美东时间
15.06
-0.190
-1.25%
华盛通- 最 高15.305
- 今 开15.19
- 成交量 20.73万股
- 最 低 15.06
- 昨 收 15.25
- 总市值 5.95亿
- 52周最高 20.7299
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 10.24
- 委 比 95.68%
- 总股本 3949.43万
- 历史最高 74.44
- 量 比 0.68
- 振 幅 1.61%
- 历史最低 9.575
- 每 手 1
- 风险率 1.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance
OrthoPediatrics Corp. announced preliminary third-quarter 2025 results, including net revenue of approximately $61.2 million, a 12% increase from the prior year. Domestic net revenue grew 14%, while international revenue rose 6%, though impacted by delayed sales in Latin and South America. The company updated its 2025 revenue guidance to $233.5 million to $234.5 million, down from earlier projections, and reaffirmed EBITDA guidance of $15 million...
10-09 20:05
Coffee Holding Company Announces the Upcoming Closing of its Comfort Foods Manufacturing Facility in North Andover, MA
Coffee Holding Co., Inc. announced the closure of its Comfort Foods manufacturing facility in North Andover, Massachusetts, by the end of this month. The facility, acquired in 2017 as a strategic move to expand production capabilities on the East Coast, has seen declining sales for its Harmony Bay product line due to reduced shelf space for regional brands in major supermarkets. The company plans to transfer production to its Second Empire facili...
10-07 13:00
OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spinal Growth Guidance System
OrthoPediatrics Corp. announced the successful completion of the first U.S. surgical procedures using the VerteGlide Spinal Growth Guidance System to treat Early Onset Scoliosis (EOS). Drs. Richard McCarthy and Kent Walker praised the system's effectiveness and potential to address an unmet clinical need. VerteGlide, part of OrthoPediatrics' Scoliosis product line, is designed to treat complex spinal pathologies and will be featured at upcoming m...
09-10 11:00
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a $16 target.
08-19 02:25
Orthofix Medical shares are trading higher after the company reported better-than-expected Q2 financial results.
Orthofix Medical shares are trading higher after the company reported better-th...
08-05 23:54
Orthofix anticipates full-year net sales of $808M–$816M while accelerating U.S. spine distributor transition
Earnings Call Insights: Orthofix Medical Inc. (OFIX) Q2 2025 Management View President and CEO Massimo Calafiore stated the company achieved second quarter pro forma net sales of $200.7 million, marki...
08-05 23:18
Orthofix Medical Affirms FY2025 Sales Guidance of $808.000M-$816.000M vs $812.800M Est
Orthofix Medical (NASDAQ:OFIX) affirms FY2025 sales outlook from $808.000 million-$816.000 million to $808.000 million-$816.000 million vs $812.800 million estimate.
08-05 19:09
Orthofix Medical Q2 Adj. EPS $0.13 Beats $(0.49) Estimate, Sales $203.121M Beat $196.890M Estimate
Orthofix Medical (NASDAQ:OFIX) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $(0.49) by 126.53 percent. This is a 160 percent increase over earnings of $0.05 per share from
08-05 19:04
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Semler Scientific's Earnings Outlook
Semler Scientific (NASDAQ:SMLR) is preparing to release its quarterly earnings ...
08-02 04:04
